Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

Now, new research from the Warren Center for Neuroscience Drug Discovery (WCNDD) offers hope. Scientists have identified a ...

Episodes usually last four to 24 hours but sometimes it can last even longer. Harvard Health warn: "Migraines often begin in ...